| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11077068 | SUNOVION PHARMS INC | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2022
(1 year, 7 months ago) | |
| US9931305 | SUNOVION PHARMS INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Feb, 2022
(1 year, 7 months ago) | |
| US10888499 | SUNOVION PHARMS INC | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
Feb, 2022
(1 year, 7 months ago) | |
| US9855221 | SUNOVION PHARMS INC | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2022
(1 year, 7 months ago) | |
| US8663687 | SUNOVION PHARMS INC | Film compositions for delivery of actives |
Feb, 2023
(7 months ago) | |
| US8765167 | SUNOVION PHARMS INC | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2024
(4 months from now) | |
| US8603514 | SUNOVION PHARMS INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(6 months from now) | |
| US10821074 | SUNOVION PHARMS INC | Sublingual and buccal film compositions |
Aug, 2029
(5 years from now) | |
| US9283219 | SUNOVION PHARMS INC | Sublingual films |
Jun, 2030
(6 years from now) | |
| US9669021 | SUNOVION PHARMS INC | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9669019 | SUNOVION PHARMS INC | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US10420763 | SUNOVION PHARMS INC | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9326981 | SUNOVION PHARMS INC | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9044475 | SUNOVION PHARMS INC | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US8846074 | SUNOVION PHARMS INC | Sublingual films |
Dec, 2031
(8 years from now) | |
| US8414922 | SUNOVION PHARMS INC | Sublingual films |
Dec, 2031
(8 years from now) | |
| US11419769 | SUNOVION PHARMS INC | Sublingual films |
Dec, 2031
(8 years from now) | |
| US10959943 | SUNOVION PHARMS INC | Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa |
Apr, 2036
(12 years from now) | |
| US10449146 | SUNOVION PHARMS INC | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
Apr, 2036
(12 years from now) | |
Kynmobi is owned by Sunovion Pharms Inc.
Kynmobi contains Apomorphine Hydrochloride.
Kynmobi has a total of 19 drug patents out of which 5 drug patents have expired.
Expired drug patents of Kynmobi are:
- US11077068
- US9931305
- US10888499
- US9855221
- US8663687
Kynmobi was authorised for market use on 21 May, 2020.
Kynmobi is available in film;sublingual dosage forms.
Kynmobi can be used as treatment of 'off' episodes in patients with parkinson's disease.
The generics of Kynmobi are possible to be released after 19 April, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | May 21, 2023 |
Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 May, 2020
Treatment: Treatment of 'off' episodes in patients with parkinson's disease
Dosage: FILM;SUBLINGUAL
KYNMOBI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic